🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

14 recruiting trials

for Relapsed Classic Hodgkin Lymphoma

MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma NCT06377540Phase 21 site📍 Minneapolis Masonic Cancer Center, University of Minnesota · Tests: Pembrolizumab, Autologous stem cell transplant, Carmustine, Etoposide, Cytarabine Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma NCT05180097Phase 218 sites📍 Concord📍 Nowra📍 Wollongong Canadian Cancer Trials Group · Tests: Gemcitabine, Dexamethasone, Cisplatin, Brentuximab vedotin, Pembrolizumab Brentuximab Vedotin and Nivolumab for the Treatment of Patients With Relapsed/Refractory Classical Hodgkin Lymphoma NCT04561206Phase 25 sites📍 Duarte📍 Chicago📍 Boston City of Hope Medical Center · Tests: Brentuximab Vedotin, Nivolumab Azacitidine Plus PD-1 Therapy for R/R Hodgkin Lymphoma NCT06190067Phase 21 site📍 Beijing Navy General Hospital, Beijing · Tests: Azacitidine Plus PD-1 therapy Study of Pembrolizumab With Bendamustine in Hodgkin Lymphoma NCT04510636Phase 21 site📍 Toronto University Health Network, Toronto · Tests: Pembrolizumab, Bendamustine Hydrochloride PD-1 Inhibitors Maintenance for cHL Post-autoHCT NCT06812858Phase 24 sites📍 Astana📍 Moscow📍 Moscow St. Petersburg State Pavlov Medical University · Tests: Nivolumab, Pembrolizumab Brentuximab Vedotin and Nivolumab for the Treatment of Relapsed/Refractory Classic Hodgkin Lymphoma Previously Treated With Brentuximab Vedotin or Checkpoint Inhibitors NCT05039073Phase 22 sites📍 Atlanta📍 Atlanta Emory University · Tests: Brentuximab Vedotin, Hematopoietic Cell Transplantation, Nivolumab, Quality-of-Life Assessment, Questionnaire Administr… Immunotherapy in Lymphoma NCT06796517n/a2 sites📍 Seoul📍 Seoul Sung-Soo Park · Tests: CAR-T Therapy, Bispecific antibody, Antibody-Drug Conjugate, Monoclonal antibody, Proteasome Inhibitor A Study of AK129 With or Without AK117 in PD(L)1-refractory Classic Hodgkin Lymphoma NCT06642792Phase 1, Phase 21 site📍 Beijing Akeso · Tests: AK129, AK117 Pembrolizumab in Combination With Salvage Chemotherapy for First-relapsed or Refractory Classical Hodgkin Lymphoma NCT04838652Phase 21 site📍 Cologne University of Cologne · Tests: Pembrolizumab plus Chemotherapy (ICE or DHAP) ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma NCT07021989Phase 26 sites📍 Davis📍 Fresno📍 Irvine Michael Spinner, MD · Tests: Pembrolizumab, Non-investigational, involved site radiotherapy (ISRT), Gemcitabine, Vinorelbine, Liposomal Doxorubicin A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051) NCT02332668Phase 1, Phase 216 sites📍 Aurora📍 Chicago📍 Boston Merck Sharp & Dohme LLC · Tests: Pembrolizumab European Project for ctDNA Detection as a Biomarker for Non-invasive Therapy Monitoring in Paediatric Classical Hodgkin Lymphoma NCT07356882n/a1 site📍 Paris Assistance Publique - Hôpitaux de Paris Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma NCT03681561Phase 1, Phase 26 sites📍 Chicago📍 Indianapolis📍 Iowa City Veronika Bachanova · Tests: Ruxolitinib, Nivolumab
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy